Biotech · Private company
Chimeric Therapeutics
Track this companyFree. Adds Chimeric Therapeutics to your Dealase workspace and tells you when its record changes.
Clinical trials21 recruiting or active
Pipeline programs2From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline2
- CHM-2101 CAR-T cellsPhase 2 · Neuroendocrine TumorsClinicalTrials.gov · fetched Nov 12, 2026
- CHM-1101 CAR-T cellsPhase 1 · Glioblastoma Multiforme of BrainClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials2
- A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell TherapyPHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started May 15, 2024ClinicalTrials.gov NCT06055439 · fetched Nov 12, 2026
- CAR T Cells in Patients With MMP2+ Recurrent or Progressive GlioblastomaPHASE1 · TERMINATED · started Jun 6, 2023ClinicalTrials.gov NCT05627323 · fetched Nov 12, 2026